KURA — Kura Oncology, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1422143 ·
Last close
$7.49
Market Cap
$688.17M
52W High
$13.90
52W Low
$6.75
ADV30
2,217,159
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 22,839,000 | 22,468,000 | -74,658,000 | -70,215,000 | 566,497,000 | 57,937,000 | 548,537,000 |
| Jun 2026 | 20,874,000 | 20,631,000 | -73,010,000 | -68,327,000 | 587,791,000 | 70,242,000 | 539,360,000 |
| Mar 2026 | 18,265,000 | 18,003,000 | -78,815,000 | -73,333,000 | 652,551,000 | 39,083,000 | 544,668,000 |
| Dec 2025 | 17,336,000 | — | -86,268,000 | -80,999,000 | 738,363,000 | 149,099,000 | 564,228,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-85,574,000
Investing CF
$12,977,000
Financing CF
$35,247,000
CapEx
$-3,550,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.30
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,385,963,000
Inventory
$4,982,000
Receivables
$14,485,000
ST Investments
$434,159,000
EBIT TTM
$-291,413,000
Pretax Income TTM
$-292,790,000
Interest Exp TTM
$1,377,000
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$79,314,000
EBITDA
$-311,295,008
Free Cash Flow
$-111,096,000
Enterprise Value
$247,631,456
Total Cash
$492,096,000
Total Debt
$25,830,000
Shares Out
91,878,694
Trailing EPS
$-3.45
Book Value
$0.20
ROE
-224.9%
ROA
-32.2%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 67,482,000 | -303,631,000 | -278,666,000 | 738,363,000 | 564,228,000 | 174,135,000 | -64,058,000 |
| Dec 2024 | 53,883,000 | -193,195,000 | -173,983,000 | 760,159,000 | 346,519,000 | 413,640,000 | 134,317,000 |
| Dec 2023 | 0 | -165,804,000 | -152,631,000 | 448,935,000 | 51,662,000 | 397,273,000 | -124,824,000 |
| Dec 2022 | 0 | -139,865,000 | -135,840,000 | 456,306,000 | 36,028,000 | 420,278,000 | -110,062,000 |
TTM Snapshot
Revenues TTM
$77,225,000
NetIncome TTM
$-296,775,000
OpCashFlow TTM
—
Assets (Latest)
$587,791,000
Forward EPS
$-2.43
Max Pain — expiry 2027-01-15
max pain strike: $11.00 · spot: $7.34 · call oi: 3,470 · put oi: 2,687
Expected Move to 2027-01-15:
±$2.05
(27.93%) —
implied range
$5.29 –
$9.39
· ATM straddle on $7.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SGMT | Sagimet Biosciences Inc. | $702.97M | $9.85 | — |
| ANNX | Annexon, Inc. | $661.95M | $3.47 | — |
| NVCT | Nuvectis Pharma, Inc. | $660.27M | $19.20 | — |
| JANX | Janux Therapeutics, Inc. | $655.27M | $10.71 | — |
| GERN | GERON CORP | $644.24M | $1.00 | — |
News headlines (Yahoo Finance, 1h cache)
Kura Oncology to Participate in Two Investor Conferences in November
2026-11-13 17:33 · Yahoo
Kura Oncology, Inc. Q3 2026 Earnings Call Summary
2026-11-11 13:30 · Yahoo
Kura Oncology Inc (KURA) (Q3 2026) Earnings Call Highlights: KOMZIFTI Revenue Surges 53% as ...
2026-11-11 07:08 · Yahoo
Kura Oncology (KURA) Q3 2026 Earnings Call Transcript
2026-11-11 05:31 · Yahoo
Kura Oncology Q3 Earnings Call Highlights
2026-11-11 01:14 · Yahoo
Kura Oncology: Q3 Earnings Snapshot
2026-11-10 21:25 · Yahoo
Kura Oncology (KURA) Reports Q3 Loss, Beats Revenue Estimates
2026-11-10 21:20 · Yahoo
Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update
2026-11-10 21:02 · Yahoo
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-06 12:30 · Yahoo
Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
2026-11-04 14:02 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-11-16 19:45:03 | 2026-11-13 | Wilson Troy Edward | Pres, CEO | P - Purchase | 7.52 | 200000 | 1504765 |